{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CASRegistryName","name":"1195765-45-7"},{"type":"ChemicalStructureName","name":"benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-"},{"type":"Synonym","name":"BRAF inhibitor GSK2118436"},{"type":"CodeName","name":"GSK 2118436"},{"type":"CodeName","name":"GSK 2118436A"},{"type":"CodeName","name":"GSK-2118436"},{"type":"CodeName","name":"GSK-2118436A"},{"type":"CodeName","name":"GSK2118436"},{"type":"CodeName","name":"GSK2118436A"}],"definition":{"html":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","text":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations."},"drugInfoSummaryLink":null,"nciConceptId":"C82386","nciConceptName":"Dabrafenib","termId":818430,"name":"dabrafenib","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"dabrafenib"},{"aliases":[{"type":"USBrandName","name":"Tafinlar"},{"type":"Synonym","name":"GSK2118436B"},{"type":"Synonym","name":"dabrafenib methanesulfonate"},{"type":"CASRegistryName","name":"1195768-06-9"},{"type":"Synonym","name":"GSK2118436 methane sulfonate salt"}],"definition":{"html":"The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","text":"The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/dabrafenib","text":"Dabrafenib Mesylate"},"nciConceptId":"C128059","nciConceptName":"Dabrafenib Mesylate","termId":641977,"name":"dabrafenib mesylate","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"dabrafenib-mesylate"}],"links":null}